# Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

> **NCT01159249** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 245 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT01159249
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01159249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01159249, "Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01159249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*